Crossover investors help Generation Bio land $110M series C to expand non-viral gene therapy platform

Since raising its $100 million series B round in 2018, Generation Bio has developed a GMP-ready manufacturing process for its non-viral gene therapies and developed a way to target them to specific tissues. The company now plans to use its $110 million series C to advance its lead hemophilia and phenylketonuria programs into the clinic and bring its platform to indications outside the liver.

Generation Bio Co. President and CEO Geoff McDonough told BioCentury an IPO could be next as “a platform like ours would very naturally require access to public markets at the right time, and for us that that’ll be in the next 12-18 months or so.” ...